GO
Loading...

Allergan Inc

More

  • Midday Glance: Medical Devices companies Wednesday, 22 Oct 2014 | 1:18 PM ET

    Allergan fell $2.44 or 1.3 percent, to $183.72. Baxter International Inc. fell$. 24 or. 3 percent, to $68.41. Boston Scientific Corp. rose$. 47 or 3.9 percent, to $12.50.

  • Early Glance: Medical Devices companies Wednesday, 22 Oct 2014 | 10:36 AM ET

    Allergan rose$. 78 or. 4 percent, to $186.94. Baxter International Inc. rose$. 17 or. 2 percent, to $68.82. Boston Scientific Corp. rose$. 37 or 3.1 percent, to $12.40.

  • Final Glance: Medical Devices companies Tuesday, 21 Oct 2014 | 6:01 PM ET

    Allergan rose $6.91 or 3.9 percent, to $186.16. Baxter International Inc. rose$. 71 or 1.0 percent, to $68.65. Medtronic rose $1.14 or 1.8 percent, to $64.98.

  • Midday Glance: Medical Devices companies Tuesday, 21 Oct 2014 | 1:43 PM ET

    Allergan rose $6.25 or 3.5 percent, to $185.50. Baxter International Inc. rose$. 28 or. 4 percent, to $68.22. Boston Scientific Corp. rose$. 31 or 2.7 percent, to $11.92.

  • Early Glance: Medical Devices companies Tuesday, 21 Oct 2014 | 11:56 AM ET

    Allergan rose $4.94 or 2.8 percent, to $184.19. Johnson& Johnson rose$. 27 or. 3 percent, to $99.47. St. Jude Medical Inc. rose$. 27 or. 5 percent, to $59.23.

  • BOSTON, Oct 21- Allergan Inc said on Tuesday it saw no evidence to support claims by hostile suitors Valeant Pharmaceuticals and hedge fund Pershing Square Capital Management that its chief executive officer had spearheaded a campaign to spread misinformation. Pershing Square, run by billionaire William Ackman, has been working with Valeant for months to...

  • Allergan says it stands by statements on Valeant Tuesday, 21 Oct 2014 | 10:45 AM ET

    BOSTON, Oct 21- Allergan Inc said on Tuesday that it believes there is no evidence to support Valeant Pharmaceuticals and hedge fund Pershing Square Capital Management's claims that its chief executive officer spearheaded a campaign to spread misinformation about Valeant.

  • BOSTON, Oct 20- Billionaire investor William Ackman, whose fund is the largest shareholder in Allergan Inc., and Valeant Pharmaceuticals said the botox maker's Chief Executive Officer David Pyott tried to discredit Valeant as it was making a hostile takeover bid, court documents showed. Ackman's hedge fund has been working with Valeant for months to craft a...

  • Final Glance: Medical Devices companies Monday, 20 Oct 2014 | 6:05 PM ET

    Allergan rose $1.76 or 1.0 percent, to $179.25. Baxter International Inc. rose$. 70 or 1.0 percent, to $67.94. Boston Scientific Corp. rose$. 24 or 2.1 percent, to $11.61.

  • Deals of the day- Mergers and acquisitions Monday, 20 Oct 2014 | 4:06 PM ET

    **Platform Specialty Products Corp said it would buy Arysta LifeScience Ltd for about $3.51 billion, Platform's third acquisition this year as the company looks to strengthen its agrichemicals business. **The top two lawmakers on the Senate's antitrust panel have urged regulators to scrutinize food distributor Sysco Corp's planned purchase of rival U.S....

  • BUSINESS-NEWS-SCHEDULE AT 1830 GMT / 2:30 p.m. ET Monday, 20 Oct 2014 | 2:52 PM ET

    International Business Machines Corp reports a marked slowdown in business in September and abandons its 2015 operating earnings target, as weak client spending and a slumping software sector weighed down quarterly revenue. Valeant Pharmaceuticals International Inc says it may raise its bid for Botox maker Allergan Inc to more than $200 per share; the...

  • Oct 20- Allergan Inc shareholder Paulson& Co is urging the Botox maker to merge with specialty pharmaceutical company Shire Plc as an alternative to a deal with hostile bidder Valeant Pharmaceuticals International Inc, according to two people familiar with the matter. The hedge fund, which earlier supported a deal with Valeant, told Allergan CEO David Pyott...

  • Midday Glance: Medical Devices companies Monday, 20 Oct 2014 | 1:23 PM ET

    Allergan rose $3.67 or 2.1 percent, to $181.16. Baxter International Inc. rose$. 18 or. 3 percent, to $67.42. Boston Scientific Corp. rose$. 13 or 1.1 percent, to $11.50.

  • Oct 20- Allergan Inc shareholder Paulson& Co is urging the Botox maker to merge with specialty pharmaceutical company Shire Plc as an alternative to a deal with hostile bidder Valeant Pharmaceuticals, according to two people familiar with the matter. The hedge fund told Allergan CEO David Pyott that it would support a deal with Shire, the sources said.

  • Report: Paulson pushing Allergan-Shire merger     Monday, 20 Oct 2014 | 12:15 PM ET

    According to Reuters sources, Allergan shareholder John Paulson is urging the company to merge with Shire. CNBC's Dominic Chu has the details.

  • Oct 20- Valeant Pharmaceuticals International Inc said on Monday that it may raise its bid for Botox maker Allergan Inc after the Canadian company posted a better-than-expected quarterly profit. Allergan stock was up 1.7 percent at $180.45. Valeant's third-quarter results were keenly anticipated for their potential impact on Valeant's bid for Allergan,...

  • Early Glance: Medical Devices companies Monday, 20 Oct 2014 | 10:40 AM ET

    Allergan rose $3.01 or 1.7 percent, to $180.50. Baxter International Inc. rose$. 02 or percent, to $67.26. Boston Scientific Corp. rose$. 05 or. 4 percent, to $11.42.

  • Oct 20- Valeant Pharmaceuticals Inc Chief Executive Michael Pearson said in an interview with Reuters on Monday that he is confident a revised bid for Allergan Inc will be worth over $200 per share, once Valeant's stock rises and with cash added to the offer. Pearson said Valeant could make a revised offer at any time and that the company's stock has been hurt by...

  • Oct 20- Canada's Valeant Pharmaceuticals International Inc, embroiled in a bitter fight to take over Botox maker Allergan Inc, posted a better-than-expected quarterly profit, driven by demand for its skin, neuro and eye drugs. The company also raised its full-year adjusted earnings forecast to $8.22- $8.32 per share from $7.90- $8.10 per share to reflect its...

  • Valeant's bid for Allergan     Monday, 20 Oct 2014 | 7:22 AM ET

    Michael Pearson, Valeant Pharmaceuticals CEO, shares his thoughts on allegations Allergan released false and misleading information.